

## **Elucidation of potential sites for antibody engineering by fluctuation editing**

Saeko Yanaka<sup>1,†</sup>, Yoshitaka Moriwaki<sup>2</sup>, Kouhei Tsumoto<sup>3,4</sup>, Kenji Sugase<sup>1,¶</sup>

<sup>1</sup>Bioorganic Research Institute, Suntory Foundation for Life Sciences. <sup>2</sup>Department of Biotechnology and Agricultural Bioinformatics Research Unit, Graduate School of Agricultural and Life Sciences, The University of Tokyo. <sup>3</sup>Department of Bioengineering, Graduate School of Engineering, The University of Tokyo. <sup>4</sup>Laboratory of Medical Proteomics, Institute of Medical Science, The University of Tokyo. Correspondence should be addressed to K.S. (sugase@moleng.kyoto-u.ac.jp)

<sup>†</sup>Currently Department of Life and Coordination-Complex Molecular Science, Biomolecular Functions, Institute of Molecular Science, National Institute of Natural Sciences.

<sup>¶</sup>Currently Department of Molecular Engineering, Graduate School of Engineering, Kyoto University.


**Supplementary Table 1 Fluctuating residues categorized by our criteria**

Small residues	L:S7(72) <sup>a</sup> , L:S54(100), L:G66(73), L:S74(46), L:G84(35), L:S91(33), L:T97(25),L:G99(7), L:G100(100), L:G101(13), H:V24(10), H:T25(85), H:S28(71), H:S31(91), H:T57(48), H:A91(0)
CDR	L:Y96(20), H:Y58(59)
Large BSA	L:F98(0), H:C22(0), H:W36(0), H:L45(11), H:Y94(2), L:Y86(0), L:H34(4), L:L47(0.0)
Selected residues	L:R45(69), H:Q3(100), H:N76(29), H:D27(69), H:R44(97), H:E46(22), H:R71(54), H:D72(46)

<sup>a</sup>The percentage of accessible surface area of residues are shown in parentheses.


## Supplementary Table 2 DSC parameters

	DSC $\Delta H$ [kcal/mol]	
	free form	complex
L:R45A	120 $\pm$ 1	302 $\pm$ 2
H:R71A	199 $\pm$ 1	313 $\pm$ 2
WT	194 $\pm$ 1	247 $\pm$ 3




### Supplementary Fig. 1 The structure of HyHEL-10.

The residues in which a single alanine-mutation was introduced in this study are colored as the following. Red: the mutants increased the affinity. Orange: the mutants were successfully refolded but the affinity increase could not be observed. Blue: the mutants could not be obtained. The V<sub>H</sub> and V<sub>L</sub> domains are shown in light green and light blue, respectively. Lysozyme is colored as gray.




**Supplementary Fig. 2 The ITC profiles of H:R71A and L:R45A titrated against lysozyme.**

The measurements were conducted at 20°C for H:R71A (a), and L:R45A (b).



**Supplementary Fig. 3 Comparison of the HSQC spectra between WT and mutants.**

(a) HSQC spectra of WT and H:R71A in the free form are shown in black and red, respectively. (b) HSQC spectra of WT and L:R45A in the free form are shown in black and green, respectively.



**Supplementary Fig. 4 DSC profiles of HyHEL-10 and its mutants.**

The DSC curves are shown for (a) WT HyHEL-10, (b) WT HyHEL-10 in complex with lysozyme, (c) L:R45A, (d) L:R45A in complex with lysozyme, (e) H:R71A, (f) H:R71A in complex with lysozyme. The red curves show the deconvolution of the experimental curves.